酪氨酸激酶抑制剂治疗慢性髓性白血病后的第二恶性肿瘤:人群趋势与结局
该回顾性研究纳入11家机构的139例伴第二恶性肿瘤的慢性髓性白血病患者,中位随访85个月,从慢性髓性白血病诊断至第二恶性肿瘤的中位时间为48个月。使用两种及以上酪氨酸激酶抑制剂是第二恶性肿瘤潜伏期的显著危险因素(OR 4.281,95%CI 1.369-13.390,p=0.012)。男性是与较差总生存(HR 0.329,95%CI 0.138-0.779,p=0.012)和无事件生存(HR 3.640,95%CI 1.485-8.925,p=0.005)相关的独立危险因素。
要点
- 139例慢性髓性白血病患者发生第二恶性肿瘤,内分泌肿瘤最常见(28.8%,40/139)。
- 使用两种及以上酪氨酸激酶抑制剂与第二恶性肿瘤潜伏期显著相关(OR 4.281,95%CI 1.369-13.390,p=0.012)。
- 男性与较差总生存(HR 0.329,95%CI 0.138-0.779,p=0.012)和无事件生存(HR 3.640,95%CI 1.485-8.925,p=0.005)独立相关。
核心结论
- 在伴第二恶性肿瘤的慢性髓性白血病患者中,男性与较差结局相关,作者认为需前瞻性研究阐明潜在生物学机制。
研究设计与样本
- 来自11家机构的回顾性研究,纳入139例伴第二恶性肿瘤的慢性髓性白血病患者。
主要发现
- 慢性髓性白血病诊断时中位年龄51岁(范围13-88岁),第二恶性肿瘤诊断时中位年龄53岁(范围18-91岁)。
- 中位随访85个月,从慢性髓性白血病诊断至第二恶性肿瘤的中位时间为48个月(范围1-264个月)。
- 使用两种及以上酪氨酸激酶抑制剂是第二恶性肿瘤潜伏期的显著危险因素(OR 4.281,95%CI 1.369-13.390,p=0.012)。
- 男性是与较差总生存相关的独立危险因素(HR 0.329,95%CI 0.138-0.779,p=0.012),也是与较差无事件生存相关的独立危险因素(HR 3.640,95%CI 1.485-8.925,p=0.005)。
- 内分泌肿瘤是最常见的亚型(28.8%,40/139);胃肠道、泌尿生殖道和皮肤恶性肿瘤显示男性优势。
局限性
- 原文未报告局限性;作者在结论中提出需前瞻性研究阐明潜在生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The life expectancy of most chronic myeloid leukaemia (CML) patients is nearly comparable to that of the general population owing to the application of tyrosine kinase inhibitors (TKIs). Hence, focus has shifted towards long-term adverse effects, especially the emergence of secondary malignancies. A retrospective study from 11 institutions was performed in 139 CML patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13-88 years) and 53 years (range, 18-91 years). After a median follow-up of 85 months, the median time from diagnosis of CML to secondary malignancy was 48 months (range, 1-264 months). The use of two or more TKIs was a significant risk factor for the latency period of secondary malignancies (odds risk [OR] of 4.281, 95% confidence interval [CI] 1.369-13.390, p = 0.012). Male sex was an independent risk factor associated with worse overall survival (hazard ratio [HR] of 0.329, 95% CI 0.138-0.779, p = 0.012) and event-free survival (HR of 3.640, 95% CI 1.485-8.925, p = 0.005). Endocrine neoplasm was the most common subtype (28.8%, 40/139). Gastrointestinal, genitourinary and cutaneous malignancies demonstrated a male predominance. Then, male sex was associated with inferior outcomes in CML patients with secondary malignancies, and prospective studies are warranted to elucidate the underlying biological mechanisms.
引用
- Zu Y, Yue X, Zhan X, et al. Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes. Br J Haematol. 2025. PMID: 40624854. doi:10.1111/bjh.20226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。